Stifel Financial Corp Sells 27,138 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Stifel Financial Corp trimmed its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 72.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,069 shares of the biotechnology company's stock after selling 27,138 shares during the quarter. Stifel Financial Corp's holdings in Sarepta Therapeutics were worth $1,224,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SRPT. Capital International Investors lifted its position in shares of Sarepta Therapeutics by 38.9% during the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after acquiring an additional 2,437,855 shares during the period. Norges Bank acquired a new position in shares of Sarepta Therapeutics during the 4th quarter valued at $126,315,000. Brandywine Global Investment Management LLC acquired a new position in shares of Sarepta Therapeutics during the 4th quarter valued at $22,613,000. Swedbank AB acquired a new position in shares of Sarepta Therapeutics during the 4th quarter valued at $16,706,000. Finally, Vanguard Group Inc. raised its holdings in Sarepta Therapeutics by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company's stock worth $1,104,701,000 after buying an additional 117,904 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Analyst Upgrades and Downgrades

SRPT has been the topic of several research reports. Evercore ISI downgraded shares of Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 price objective on the stock. in a report on Thursday. Oppenheimer lowered their price objective on shares of Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Wells Fargo & Company lowered their price objective on shares of Sarepta Therapeutics from $115.00 to $100.00 and set an "overweight" rating on the stock in a report on Thursday. Guggenheim reduced their target price on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, Royal Bank of Canada reduced their target price on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a "sector perform" rating for the company in a research note on Wednesday, May 7th. Six investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $131.22.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT traded up $0.10 during trading on Monday, hitting $36.37. 8,354,950 shares of the company's stock traded hands, compared to its average volume of 1,648,041. The stock has a market capitalization of $3.57 billion, a price-to-earnings ratio of 29.10 and a beta of 0.85. Sarepta Therapeutics, Inc. has a 12-month low of $35.46 and a 12-month high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The business has a 50 day moving average of $66.84 and a 200-day moving average of $100.44.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The business had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. Sarepta Therapeutics's revenue for the quarter was up 80.2% compared to the same quarter last year. During the same period last year, the company earned $0.73 earnings per share. As a group, equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Insider Transactions at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now directly owns 27,812 shares of the company's stock, valued at $2,771,187.68. This trade represents a 8.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.